• Wondering if AbbVie at around US$213.76 is giving you good value for the risk you are taking, or if the price is already baking in most of the story?
• The stock recently closed at US$213.76, with returns of 2.8% over 7 days, 2.6% over 30 days, a decline of 6.8% year to date, and 19.4% over 1 year. This gives you a mixed picture of recent momentum and risk sentiment.
• Recent coverage has focused on AbbVie as a large US pharmaceuticals and biotech stock, with investors paying attention to how its product portfolio and pipeline position it within the sector. This context is important when thinking about why the stock has moved the way it has in the short term and over the last year.
• Right now, AbbVie scores a 2 out of 6 valuation score. The next sections will look at what different valuation methods say about that number, and finish with a way of looking at valuation that can give you a fuller picture than any single metric alone.

AbbVie scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: AbbVie Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and discounting them back to today using a required rate of return. It focuses on cash that could, in theory, be returned to shareholders over time.

For AbbVie, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $20.1b. Analyst estimates underpin projected free cash flow of $26.7b in 2026 and $32.5b in 2027, with further projections out to 2035 extrapolated by Simply Wall St, reaching $34.3b in 2030 and $39.1b in 2035. All figures are in US$.

Discounting those future cash flows back to today gives an estimated intrinsic value of $420.91 per share. Compared with the recent share price of about $213.76, the DCF output suggests the stock is 49.2% undervalued on this cash flow view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests AbbVie is undervalued by 49.2%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks.

Approach 2: AbbVie Price vs Earnings (P/E)

For profitable companies, the P/E ratio is a useful way to think about what you are paying for each dollar of current earnings. This makes it a common starting point when you compare stocks within the same sector.

What counts as a “normal” P/E depends on what investors expect from a company and how much risk they see. Higher growth expectations or lower perceived risk can support a higher P/E, while slower expected growth or higher risk usually lines up with a lower P/E.

AbbVie currently trades on a P/E of 105.05x. That sits well above the Biotechs industry average of 17.27x and above the peer average of 20.09x, so on simple comparisons the stock trades on a richer multiple than many peers.

Simply Wall St’s Fair Ratio for AbbVie is 36.91x. This is a proprietary estimate of what AbbVie’s P/E might be given factors such as its earnings growth profile, profit margins, industry, market cap and identified risks. Because it blends these elements, the Fair Ratio is designed to be more tailored than a basic peer or industry comparison.

Comparing AbbVie’s current P/E of 105.05x with the Fair Ratio of 36.91x points to the stock trading above that tailored estimate.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your AbbVie Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St give you a clear story behind the numbers by letting you link your view on AbbVie’s future revenue, earnings and margins to a forecast and then to your own fair value that you can compare against the current price.

On the Community page, you can pick or create a Narrative that matches how you see AbbVie. Whether you lean closer to the bullish analyst fair value of about US$299, think the more cautious US$184 is more realistic, or sit around the consensus of roughly US$249, the platform will turn that story into a set of forecasts and a fair value estimate that updates when new earnings, news or guidance come through. This can help you decide whether the current price lines up with the risk and return trade off you are comfortable with.

Do you think there's more to the story for AbbVie? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.